Alan Carl Foster

Alan Carl Foster's AcademicInfluence.com Rankings

Alan Carl Foster

Biology

#13082

World Rank

#16607

Historical Rank

Neuroscience

#2246

World Rank

#2307

Historical Rank

biology Degrees

Download Badge

Biology

Why Is Alan Carl Foster Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Alan Carl Foster's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Acidic amino acid binding sites in mammalian neuronal membranes: their characteristics and relationship to synaptic receptors (1984) (802)
Amino acid neurotransmitters and their pathways in the mammalian central nervous system (1983) (642)
7-Chlorokynurenic acid is a selective antagonist at the glycine modulatory site of the N-methyl-D-aspartate receptor complex. (1988) (510)
Non-competitive antagonists of excitatory amino acid receptors (1987) (506)
The novel anticonvulsant MK‐801 binds to the activated state of the N‐methyl‐d‐aspartate receptor in rat brain (1987) (449)
II: Excitotoxic models for neurodegenerative disorders (1984) (445)
Kynurenic acid blocks neurotoxicity and seizures induced in rats by the related brain metabolite quinolinic acid (1984) (402)
Fractalkine (CX3CL1) and fractalkine receptor (CX3CR1) distribution in spinal cord and dorsal root ganglia under basal and neuropathic pain conditions (2004) (367)
Inhibition of TNF-alpha expression by adenosine: role of A3 adenosine receptors. (1996) (357)
Gene expression analyses reveal molecular relationships among 20 regions of the human CNS (2006) (342)
Evidence that exogenous and endogenous fractalkine can induce spinal nociceptive facilitation in rats (2004) (286)
MK-801 is neuroprotective in gerbils when administered during the post-ischaemic period (1988) (274)
Excitatory amino acid synaptic mechanisms and neurological function (1986) (231)
Taking apart NMDA receptors (1987) (200)
Synaptic localization of kainic acid binding sites (1981) (197)
On the excitotoxic properties of quinolinic acid, 2,3-piperidine dicarboxylic acids and structurally related compounds (1983) (196)
Identification of quinolinic acid in rat and human brain tissue (1983) (183)
Corticotropin Releasing Hormone Type 2 Receptors in the Dorsal Raphe Nucleus Mediate the Behavioral Consequences of Uncontrollable Stress (2003) (182)
Glutamate- and GABA-based CNS therapeutics. (2006) (182)
Excitotoxic models for neurodegenerative disorders. (1984) (168)
4-Amido-2-carboxytetrahydroquinolines. Structure-activity relationships for antagonism at the glycine site of the NMDA receptor. (1992) (157)
The interaction between MK-801 and receptors for n-methyl-d-aspartate : Functional consequences (1987) (156)
Role of corticotropin-releasing factor (CRF) receptors in the anorexic syndrome induced by CRF. (2000) (154)
Pharmacological evidence supporting a role for central corticotropin-releasing factor(2) receptors in behavioral, but not endocrine, response to environmental stress. (2002) (148)
Systemic administration of MK-801 prevents N-methyl-d-aspartate-induced neuronal degeneration in rat brain (1987) (145)
Seizure activity and lesions after intrahippocampal quinolinic acid injection (1984) (143)
Effect of plasma protein binding on in vivo activity and brain penetration of glycine/NMDA receptor antagonists. (1997) (132)
Enantiomers of HA-966 (3-amino-1-hydroxypyrrolid-2-one) exhibit distinct central nervous system effects: (+)-HA-966 is a selective glycine/N-methyl-D-aspartate receptor antagonist, but (-)-HA-966 is a potent gamma-butyrolactone-like sedative. (1990) (131)
Synthesis of Quinolinic Acid by 3‐Hydroxyanthranilic Acid Oxygenase in Rat Brain Tissue In Vitro (1986) (127)
High-Affinity CRF1 Receptor Antagonist NBI-34041: Preclinical and Clinical Data Suggest Safety and Efficacy in Attenuating Elevated Stress Response (2007) (126)
Kynurenic acid derivatives. Structure-activity relationships for excitatory amino acid antagonism and identification of potent and selective antagonists at the glycine site on the N-methyl-D-aspartate receptor. (1991) (122)
Chloride and calcium ions reveal a pharmacologically distinct population of L-glutamate binding sites in synaptic membranes: correspondence between biochemical and electrophysiological data (1982) (121)
Behavioral and neuroendocrine effects of the selective CRF2 receptor agonists urocortin II and urocortin III (2004) (118)
3'-(Arylmethyl)- and 3'-(aryloxy)-3-phenyl-4-hydroxyquinolin-2(1H)-ones: orally active antagonists of the glycine site on the NMDA receptor. (1994) (115)
Comparison of L-[3H]glutamate, D-[3H]aspartate, DL-[3H]AP5 and [3H]NMDA as ligands for NMDA receptors in crude postsynaptic densities from rat brain. (1987) (108)
Studies on the disposition of quinolinic acid after intracerebral or systemic administration in the rat (1984) (106)
Urocortin, corticotropin releasing factor-2 receptors and energy balance. (2001) (104)
Indiplon Is a High-Affinity Positive Allosteric Modulator with Selectivity for α1 Subunit-Containing GABAA Receptors (2006) (104)
Pharmacological specificity of synthetic peptides as antagonists at tachykinin receptors (1988) (102)
Delayed treatment with an adenosine kinase inhibitor, GP683, attenuates infarct size in rats with temporary middle cerebral artery occlusion. (1998) (100)
Displacement of insulin-like growth factors from their binding proteins as a potential treatment for stroke. (1998) (95)
Adenosine kinase inhibitors as a novel approach to anticonvulsant therapy. (1999) (95)
The regulation of feeding and metabolic rate and the prevention of murine cancer cachexia with a small-molecule melanocortin-4 receptor antagonist. (2005) (88)
Quinolinic acid phosphoribosyltransferase in human and rat brain: Activity in Huntington's disease and in quinolinate-lesioned rat striatum (1985) (85)
2-Carboxytetrahydroquinolines. Conformational and stereochemical requirements for antagonism of the glycine site on the NMDA receptor. (1992) (78)
Characterization of the binding of [3H]L-689,560, an antagonist for the glycine site on the N-methyl-D-aspartate receptor, to rat brain membranes. (1992) (76)
Quinolinic Acid Phosphoribosyltransferase in Rat Brain (1985) (75)
Glutamate and aspartate binding sites are enriched in synaptic junctions isolated from rat brain (1981) (75)
Chloride and calcium ions separate L-glutamate receptor populations in synaptic membranes. (1983) (70)
Kynurenic acid analogues with improved affinity and selectivity for the glycine site on the N-methyl-D-aspartate receptor from rat brain. (1992) (69)
3-Nitro-3,4-dihydro-2(1H)-quinolones. Excitatory amino acid antagonists acting at glycine-site NMDA and (RS)-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors. (1993) (68)
Anticonvulsant activity of glycine-site NMDA antagonists. 2. trans 2-carboxy-4-substituted tetrahydroquinolines. (1993) (68)
Peripheral administration of the melanocortin-4 receptor antagonist NBI-12i ameliorates uremia-associated cachexia in mice. (2007) (64)
In Vivo Pharmacological Characterization of Indiplon, a Novel Pyrazolopyrimidine Sedative-Hypnotic (2004) (61)
Central infusion of the melanocortin receptor antagonist agouti-related peptide (AgRP(83-132)) prevents cachexia-related symptoms induced by radiation and colon-26 tumors in mice (2007) (58)
Neuroprotective Effects of Insulin-Like Growth Factor-Binding Protein Ligand Inhibitors in Vitro and in Vivo (2003) (58)
Identification of differentially expressed genes induced by transient ischemic stroke. (2002) (57)
Glycine maintains excitement (1989) (57)
4-substituted-3-phenylquinolin-2(1H)-ones: acidic and nonacidic glycine site N-methyl-D-aspartate antagonists with in vivo activity. (1997) (51)
Pre-and peristroke treatment with the adenosine kinase inhibitor, 5′-deoxyiodotubercidin, significantly reduces infarct volume after temporary occlusion of the middle cerebral artery in rats (1996) (50)
Corticotropin‐releasing factor receptor 1‐deficient mice show decreased anxiety and colonic sensitivity (2007) (50)
Characterization of the Interaction of Indiplon, a Novel Pyrazolopyrimidine Sedative-Hypnotic, with the GABAA Receptor (2004) (50)
Characterization of Novel Aryl-Ether, Biaryl, and Fluorene Aspartic Acid and Diaminopropionic Acid Analogs as Potent Inhibitors of the High-Affinity Glutamate Transporter EAAT2 (2005) (48)
[3H]MK‐801 Binding to N‐Methyl‐d‐Aspartate Receptors Solubilized from Rat Brain: Effects of Glycine Site Ligands, Polyamines, Ifenprodil, and Desipramine (1991) (43)
D-Serine Is a Substrate for Neutral Amino Acid Transporters ASCT1/SLC1A4 and ASCT2/SLC1A5, and Is Transported by Both Subtypes in Rat Hippocampal Astrocyte Cultures (2016) (42)
An investigation of the mechanisms of delayed neurodegeneration caused by direct injection of quinolinate into the rat striatum in vivo (1991) (42)
Allosteric modulation of the glutamate site on the NMDA receptor by four novel glycine site antagonists. (1995) (41)
Role of the GLT‐1 subtype of glutamate transporter in glutamate homeostasis: the GLT‐1‐preferring inhibitor WAY‐855 produces marginal neurotoxicity in the rat hippocampus (2005) (40)
The expression of excitatory amino acid binding sites during neuritogenesis in the developing rat cerebellum. (1990) (38)
Identification of Synapse Specific Components: Synaptic Glycoproteins, Proteins, and Transmitter Binding Sites (1981) (37)
An evaluation of the role of extracellular amino acids in the delayed neurodegeneration induced by quinolinic acid in the rat striatum (1993) (36)
Regulation of glutamate receptors: possible role of phosphatidylserine (1982) (36)
Endogenous Amino Acid Release from Rat Cerebellum In Vitro (1980) (35)
[3H]Glycine uptake in rat hippocampus: kinetic analysis and autoradiographic localization (1992) (35)
MK-801, NMDA receptors and ischaemia-induced neurodegeneration (1987) (34)
Characterization of Quinolinic Acid Phosphoribosyltransferase in Human Blood and Observations in Huntington's Disease (1985) (32)
Effects of a selective agonist and antagonist of CRF2 receptors on cardiovascular function in the rat. (2003) (31)
4-{(2R)-[3-Aminopropionylamido]-3-(2,4-dichlorophenyl)propionyl}-1-{2-[(2-thienyl)ethylaminomethyl]phenyl}piperazine as a potent and selective melanocortin-4 receptor antagonist--design, synthesis, and characterization. (2004) (29)
Over‐expression of the human EAAT2 glutamate transporter within neurons of mouse organotypic hippocampal slice cultures leads to increased vulnerability of CA1 pyramidal cells (2005) (28)
Neurobiology. Taking apart NMDA receptors. (1987) (28)
Pharmacological characterization of threo‐3‐methylglutamic acid with excitatory amino acid transporters in native and recombinant systems (2001) (28)
Expression profile of the copper homeostasis gene, rAtox1, in the rat brain (1999) (27)
A radioenzymatic assay for quinolinic acid. (1986) (27)
Body Weight Regulation by Selective MC4 Receptor Agonists and Antagonists (2003) (26)
Quisqualate receptor antagonists (1988) (26)
Molecular interactions of nonpeptide agonists and antagonists with the melanocortin-4 receptor. (2005) (25)
BDNF, NT-3 and Trk receptor agonist monoclonal antibodies promote neuron survival, neurite extension, and synapse restoration in rat cochlea ex vivo models relevant for hidden hearing loss (2019) (25)
Amino acid bioisosteres: design of 2-quinolone derivatives as glycine-site N-methyl-D-aspartate receptor antagonists (1993) (25)
Expression of rat insulin-like growth factor binding protein-6 in the brain, spinal cord, and sensory ganglia. (2000) (25)
Potent and orally active non-peptide antagonists of the human melanocortin-4 receptor based on a series of trans-2-disubstituted cyclohexylpiperazines. (2005) (25)
Autoradiographical analysis of excitatory amino acid binding sites in rat hippocampus during the development of hippocampal kindling (1990) (25)
L-glutamate and l-aspartate bind to separate sites in rat brain synaptic membranes (1981) (24)
Melanocortin-4 receptor antagonists as potential therapeutics in the treatment of cachexia. (2007) (24)
The pharmacological specificity of N‐methyl‐d‐aspartate receptors in rat cerebral cortex: correspondence between radioligand binding and electrophysiological measurements (1991) (24)
A Novel Cell-Based Assay for G-Protein-Coupled Receptor-Mediated Cyclic Adenosine Monophosphate Response Element Binding Protein Phosphorylation (2006) (22)
Piperazinebenzylamines as potent and selective antagonists of the human melanocortin-4 receptor. (2004) (22)
Comparison of the binding of radiolabelled neurokinin A and eledoisin in rat cortex synaptic membranes (1988) (22)
Plasma and CSF levels of dizocilpine (MK-801) required for neuroprotection in the quinolinate-injected rat striatum. (1991) (21)
Structure-activity relationships of piperazinebenzylamines as potent and selective agonists of the human melanocortin-4 receptor. (2004) (21)
Neuroprotective Effects of the CRF1 Antagonist R121920 after Permanent Focal Ischemia in the Rat (2001) (20)
Pharmacological and pharmacokinetic characterization of 2-piperazine-alpha-isopropyl benzylamine derivatives as melanocortin-4 receptor antagonists. (2008) (20)
Discovery of 1-[2-[(1S)-(3-dimethylaminopropionyl)amino-2-methylpropyl]-4-methylphenyl]-4-[(2R)-methyl-3-(4-chlorophenyl)-propionyl]piperazine as an orally active antagonist of the melanocortin-4 receptor for the potential treatment of cachexia. (2007) (19)
Structure-activity relationships of l-glutamate receptor ligands: Role of the ω-acidic terminal (1982) (19)
The Effect of GP683, an Adenosine Kinase Inhibitor, on the Desflurane Anesthetic Requirement in Dogs (1997) (19)
Corticotropin-releasing factor: effect on cerebral blood flow in physiologic and ischaemic conditions (2005) (19)
NMDA receptors assessed by autoradiography with [3H]L-689,560 are present but not enriched on corticofugal-projecting pyramidal neurones (1992) (19)
A potent and selective nonpeptide antagonist of the melanocortin-4 receptor induces food intake in satiated mice. (2005) (18)
Arylpropionylpiperazines as antagonists of the human melanocortin-4 receptor. (2006) (18)
Multiple Receptors and Binding Sites for Tachykinins (1987) (18)
Studies on the structure-activity relationship of bicifadine analogs as monoamine transporter inhibitors. (2008) (18)
MC4 receptor antagonists: a potential treatment for cachexia. (2005) (16)
Derivatives of 1-hydroxy-3-aminopyrrolidin-2-one (HA-966). Partial agonists at the glycine site of the NMDA receptor (1993) (16)
Phenylglycine analogs are inhibitors of the neutral amino acid transporters ASCT1 and ASCT2 and enhance NMDA receptor-mediated LTP in rat visual cortex slices (2017) (16)
3′‐(Arylmethyl)‐ and 3′‐(Aryloxy)‐3‐phenyl‐4‐hydroxyquinolin‐2(1H)‐ ones: Orally Active Antagonists of the Glycine Site on the NMDA Receptor. (2010) (15)
Design, synthesis, in vitro, and in vivo characterization of phenylpiperazines and pyridinylpiperazines as potent and selective antagonists of the melanocortin-4 receptor. (2007) (15)
The Neurodegenerative Properties Of Intracerebral Quinolinic Acid And Its Structural Analog Cis-2,3-Piperidine Dicarboxylic Acid (1983) (15)
Identification of 1S,2R-milnacipran analogs as potent norepinephrine and serotonin transporter inhibitors. (2008) (15)
Identification and characterization of pyrrolidine diastereoisomers as potent functional agonists and antagonists of the human melanocortin-4 receptor. (2008) (14)
Synthesis and characterization of pyrrolidine derivatives as potent agonists of the human melanocortin-4 receptor. (2007) (13)
Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor. (2007) (13)
Studies on the SAR and pharmacophore of milnacipran derivatives as monoamine transporter inhibitors. (2008) (13)
Blockade of excitatory amino acid transporters in the rat hippocampus results in enhanced activation of group I and group III metabotropic glutamate receptors (2003) (12)
Phenylguanidines as selective nonpeptide melanocortin-5 receptor antagonists. (2004) (12)
Acidic amino acid receptor nomenclature: time for change (1988) (12)
Pyrrolidinones as orally bioavailable antagonists of the human melanocortin-4 receptor with anti-cachectic activity. (2007) (11)
Identification of agonists and antagonists of the human melanocortin-4 receptor from piperazinebenzylamines. (2005) (11)
Propionylpiperazines as human melanocortin-4 receptor ligands. (2006) (10)
2-carboxy indolines and indoles as potential glycine/NMDA antagonists: effect of five-membered ring conformation on affinity. (1992) (10)
The glycine site on the NMDA receptor: pharmacology and involvement in NMDA receptor-mediated neurodegeneration. (1990) (10)
Discrimination of Excitatory Amino Acid Receptor Sub-types Using Radioligand Binding Techniques (1986) (10)
Characterization of thien-2-yl 1S,2R-milnacipran analogues as potent norepinephrine/serotonin transporter inhibitors for the treatment of neuropathic pain. (2008) (9)
Design and synthesis of 3-arylpyrrolidine-2-carboxamide derivatives as melanocortin-4 receptor ligands. (2008) (9)
Studies on a series of milnacipran analogs containing a heteroaromatic group as potent norepinephrine and serotonin transporter inhibitors. (2008) (9)
Inhibitors of the Neutral Amino Acid Transporters ASCT1 and ASCT2 Are Effective in In Vivo Models of Schizophrenia and Visual Dysfunction (2018) (8)
Structure-activity relationship of a series of cyclohexylpiperidines bearing an amide side chain as antagonists of the human melanocortin-4 receptor. (2005) (8)
Optimization of piperazinebenzylamines with a N-(1-methoxy-2-propyl) side chain as potent and selective antagonists of the human melanocortin-4 receptor. (2005) (8)
Therapeutic potential of NMDA receptor antagonists as neuroprotective agents. (1990) (8)
Activity of the enantiomers of erythro‐3‐hydroxyaspartate at glutamate transporters and NMDA receptors (2016) (7)
Targeting melanocortin receptors for the treatment of obesity (2006) (7)
Autoradiographical evaluation of [3H]glycine uptake in rat forebrain: Cellular localization in the hippocampus (1993) (7)
Ischemic preconditioning reduces infarct volume after subdural hematoma in the rat (2002) (6)
trans-2-Carboxy-4-substituted Tetrahydroquinolines. Potent Glycine- Site NMDA Receptor Antagonists. (1991) (6)
Structure-activity relationship studies on a series of cyclohexylpiperazines bearing a phanylacetamide as ligands of the human melanocortin-4 receptor. (2005) (6)
Physiology and pathophysiology of excitatory amino acid neurotransmitter systems in relation to Alzheimer's disease. (1990) (5)
A comment on the classification and nomenclature of phencyclidine and sigma receptor sites (1988) (5)
Regulation of endogenous adenosine levels in the CNS: potential for therapy in stroke, epilepsy and pain. (1994) (5)
6.04 – Anxiety (2007) (5)
3-Acyl-4-hydroxyquinolin-2(1H)-ones. Systemically Active Anticonvulsants Acting by Antagonism at the Glycine Site of the N- Methyl-D-aspartate Receptor Complex. (1994) (5)
4‐Substituted‐3‐phenylquinolin‐2(1H)‐ones: Acidic and Nonacidic Glycine Site N‐Methyl‐D‐aspartate Antagonists with in vivo Activity. (1997) (5)
Neurobiology. Glycine maintains excitement. (1989) (4)
Design, synthesis, and SAR studies on a series of 2-pyridinylpiperazines as potent antagonists of the melanocortin-4 receptor. (2006) (4)
Quinolinate And Kynurenate, Two Endogenous Tryptophan Metabolites With Potential Links To Epileptic Disorders (1984) (4)
A neurotrophic approach to treating hearing loss: Translation from animal models to clinical proof-of-concept. (2022) (4)
Involvement of excitatory amino acid receptors in the mechanisms underlying excitotoxic phenomena. (1986) (4)
3-aminoglutarate is a “silent” false transmitter for glutamate neurons (2015) (4)
STUDIES OF QUINOLINIC ACID METABOLISM IN RAT BRAIN (1984) (4)
Effects of 3-aminoglutarate, a “silent” false transmitter for glutamate neurons, on synaptic transmission and epileptiform activity (2015) (4)
Restoration of visual performance by d-serine in models of inner and outer retinal dysfunction assessed using sweep VEP measurements in the conscious rat and rabbit (2016) (4)
Glutamate- and GABA-based drugs: the next wave of CNS therapeutics? (2006) (3)
Biochemical and morphological aspects of kainic acid injection into rat cerebellum [proceedings]. (1979) (2)
Hearing loss: The final frontier of pharmacology (2022) (2)
Therapeutic neuroprotection by an engineered neurotrophin designed to broadly activate Trk-receptors and to circumvent p75 receptors. (2021) (2)
Synthesis of Piperazinephen-1-ylethylamines as Potent and Selective Antagonists of the Human Melanocortin-4 Receptor (2006) (2)
Structure--activity relationships of L-glutamate receptor ligands: role of the omega-acidic terminal. (1982) (1)
Therapeutic Neuroprotection by an Engineered Neurotrophin that Selectively Activates Tropomyosin Receptor Kinase (Trk) Family Neurotrophin Receptors but Not the p75 Neurotrophin Receptor (2021) (1)
Pharmacological Enhancement of LTP in Primary Visual Cortex via activation of Alpha 2a/c Adrenergic Receptors (2012) (0)
An apparatus for examining an enclosure in metal magnetic (1976) (0)
Glutamic acid: High-affinity binding tocerebellar membranes (1977) (0)
Neurobiology. Quisqualate receptor antagonists. (1988) (0)
Chapter 10 Glutamate receptors (1993) (0)
Geraet for inspection of intake trim of a vessel (1976) (0)
Neuromuscular spedfldty: pathflnding by identified motor growth cones in a vertebrate embryo (1988) (0)
Adenosine-Based Approaches to the Treatment of Neurodegenerative Disease (2002) (0)
Transporter inhibitors D-serine as pharmaceutical compositions for the treatment of disorders of the central nervous system (2012) (0)
AN ADVANCED TRAVELLER INFORMATION SYSTEM FOR THE CHRYSLER TECHNOLOGY CENTER (1996) (0)
Determination off the potencies of the R-(+) and S-(−) enantiomers off HA-966 as antagonists of the glycine site on the NMDA receptor complex (1990) (0)
933 – L-3H-GLUTAMATE BINDING TO CEREBELLAR MEMBRANE PREPARATIONS (1978) (0)
System for gefaessuntersuchung (1976) (0)
SHORT COMMUNICATION Over-expression of the human EAAT2 glutamate transporter within neurons of mouse organotypic hippocampal slice cultures leads to increased vulnerability of CA1 pyramidal cells (2005) (0)
Glutamic acid: high-affinity binding to cerebellar membranes [proceedings]. (1977) (0)
Remote controlled device for inspecting connections sodas (1976) (0)
Fjerrmanovrerad apparatus for inspecting the connection between a conduit and Veggen of a kerl (1976) (0)

This paper list is powered by the following services:

Alan Carl Foster's Academic­Influence.com Rankings

Why Is Alan Carl Foster Influential?

Alan Carl Foster's Published Works

Published Works

Alan Carl Foster's AcademicInfluence.com Rankings